AU2015264325B2 - Enantiopure haptens for nicotine vaccine development - Google Patents

Enantiopure haptens for nicotine vaccine development Download PDF

Info

Publication number
AU2015264325B2
AU2015264325B2 AU2015264325A AU2015264325A AU2015264325B2 AU 2015264325 B2 AU2015264325 B2 AU 2015264325B2 AU 2015264325 A AU2015264325 A AU 2015264325A AU 2015264325 A AU2015264325 A AU 2015264325A AU 2015264325 B2 AU2015264325 B2 AU 2015264325B2
Authority
AU
Australia
Prior art keywords
nicotine
hapten
formula
vaccine
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2015264325A
Other languages
English (en)
Other versions
AU2015264325A1 (en
Inventor
Kim D. Janda
Jonathan W. LOCKNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2015264325A1 publication Critical patent/AU2015264325A1/en
Application granted granted Critical
Publication of AU2015264325B2 publication Critical patent/AU2015264325B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015264325A 2014-05-19 2015-05-19 Enantiopure haptens for nicotine vaccine development Expired - Fee Related AU2015264325B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000312P 2014-05-19 2014-05-19
US62/000,312 2014-05-19
PCT/US2015/031583 WO2015179403A1 (en) 2014-05-19 2015-05-19 Enantiopure haptens for nicotine vaccine development

Publications (2)

Publication Number Publication Date
AU2015264325A1 AU2015264325A1 (en) 2016-12-01
AU2015264325B2 true AU2015264325B2 (en) 2019-02-14

Family

ID=54554631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015264325A Expired - Fee Related AU2015264325B2 (en) 2014-05-19 2015-05-19 Enantiopure haptens for nicotine vaccine development

Country Status (8)

Country Link
US (3) US20170107275A1 (https=)
EP (1) EP3145920B1 (https=)
JP (1) JP6564396B2 (https=)
KR (1) KR102435658B1 (https=)
CN (2) CN110452217B (https=)
AU (1) AU2015264325B2 (https=)
CA (1) CA2949667C (https=)
WO (1) WO2015179403A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107275A1 (en) 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN118161604B (zh) * 2024-03-25 2025-01-14 海南大学 一种尼古丁蛋白缀合物、其制备方法及在疫苗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032239A1 (en) * 1998-12-01 2000-06-08 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US7446205B2 (en) * 2005-11-28 2008-11-04 Nabi Biopharmaceuticals Method for making nicotine hapten
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US7820826B2 (en) * 2006-03-29 2010-10-26 North Carolina State University Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives
TWI578997B (zh) * 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
US20170107275A1 (en) 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
US9884114B2 (en) * 2015-06-23 2018-02-06 Arizona Board Of Regents On Behalf Of Arizona State University Methods of rational nicotine hapten design and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032239A1 (en) * 1998-12-01 2000-06-08 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US7446205B2 (en) * 2005-11-28 2008-11-04 Nabi Biopharmaceuticals Method for making nicotine hapten
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID C. PRYDE ET AL, "Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice", PLOS ONE, (2013-10-01), vol. 8, no. 10, doi:10.1371/journal.pone.0076557, page e76557 *

Also Published As

Publication number Publication date
CN110452217A (zh) 2019-11-15
KR102435658B1 (ko) 2022-08-23
JP6564396B2 (ja) 2019-08-21
EP3145920A1 (en) 2017-03-29
CN110452217B (zh) 2022-12-27
US20190119363A1 (en) 2019-04-25
US10487141B2 (en) 2019-11-26
CN106458971A (zh) 2017-02-22
JP2017515867A (ja) 2017-06-15
US20170107275A1 (en) 2017-04-20
CA2949667C (en) 2022-05-03
WO2015179403A1 (en) 2015-11-26
AU2015264325A1 (en) 2016-12-01
EP3145920B1 (en) 2019-09-18
US20180086820A1 (en) 2018-03-29
CA2949667A1 (en) 2015-11-26
KR20170007810A (ko) 2017-01-20
EP3145920A4 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
US6518031B2 (en) Hapten-carrier conjugates for treating and preventing nicotine addiction
US10487141B2 (en) Enantiopure haptens for nicotine vaccine development
US6210677B1 (en) Method to reduce the physiologic effects of drugs on mammals
HK1075824A (en) Hapten-carrier conjugates for treating and preventing nicotine addiction
HK1091415B (en) Hapten-carrier conjugates for treating and preventing nicotine addiction

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee